Efficacy of an Antiaging Treatment Against Environmental Factors: Deschampsia antarctica Extract and High-tolerance Retinoids Combination.

Background. Effects of environmental contaminents, such as air pollution and cigarette smoking on skin include increased oxidation, subclinical inflammation, and degradation of the dermal matrix, which can accelerate the skin aging process. Objective. An open-label, prospective study was conducted to assess the efficacy and tolerability of a topical anti-aging regimen comprising high-concentration retinoids, Deschampsia antarctica extract, and niacinamide in participants living in a heavily polluted (Level III, World Health Organization) city. Methods. Twenty-two female Caucasian volunteers with Fitzpatrick Skin Types III and IV were treated for 90 days with the topical anti-aging regimen. Subjective clinical assessments using the Rao-Goldman Scoring for Facial Aging, Patient's Global Assessment (PGA), and Investigator's Global Assessment (IGA). Additionally, objective instrumental assessments for wrinkles using Visia® (Canfield Scientific, Parsippany, New Jersey) and Visioline® (Courage+Khazaka Electronic GmbH, Cologne, Germany) and viscoelasticity and firmness using Cutometer® (Courage+Khazaka Electronic GmbH ) were completed at baseline, Day 30, and Day 90. Results. At Day 30, wrinkles in the periocular area significantly improved by 35.7 percent (p=0.003) compared to baseline. At the end of the study (Day 90), a significant improvement in firmness (41.7%) and viscoelasticity (12.8%) were observed. Tolerance for treatment was assessed as "good" or "very good" in 86.5 percent of the volunteers. Conclusion. This novel antiaging treatment regimen could potentially serve as an effective and long-term topical treatment option for improving signs of facial aging and protecting the skin from external factors associated with acceleration of the skin aging process, such exposure to UV radiation, air pollution, and cigarette smoke. Larger and longer-term, randomized, controlled clinical trials in more diverse population samples are needed to confirm our results.

Assessment of the efficacy and tolerance of an innovative regenerative serum on cutaneous regeneration, following fractional laser procedure using Erbium:YAG.

INTRODUCTION: Cutaneous regeneration, fractional laser, medical device, cellular proliferation cutaneous changes linked to photoaging are currently treated with physical treatments, such as fractional laser, which may induce epidermal alteration. OBJECTIVE: To determine the efficacy and safety of a regenerative serum (Matricium® , Laboratoire Bioderma, France) after laser procedure. METHODS: Prospective, double-blind, controlled, and randomized study in subjects with photoaged skin. The regenerative serum of treatment was used after a fractional laser session twice daily for 2 months on 1 side of the face and the placebo on the other side. The main variable to determine efficacy was the improvement of clinical signs and histological and immunological results. RESULTS: A superior quality of epidermal regeneration on the treated side compared to the placebo side was observed. Likewise, a superior and faster clinical improvement on static wrinkles was observed on the hemiface on which the regenerative serum was used. After 60 days, the investigator and the subjects observed a moderate to significant improvement of the skin on the treated side and a mild to moderate improvement on the placebo side. Histological examinations showed a superior thickness of epidermis and higher cellular proliferation rate (Ki67 markers) as well as a superior thickness of dermis with higher increase in elastin density with the regenerative serum compared to placebo. CONCLUSION: The use of the regenerative serum after fractional laser on the face accelerated and improved the cutaneous regeneration on both the clinical and histological level and maximized the benefits of the laser procedure.

Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma.

BACKGROUND: Melasma is a dermatosis with significant repercussions on patients' quality of life, and there is currently no standard treatment. Hydroquinone is deemed the treatment of choice, but its safety has been questioned in certain cases. AIMS: To determine the efficacy and safety of a new combination of retinoids in the improvement of melasma. PATIENTS/METHODS: Prospective, double-blind, vehicle-controlled, and randomized study in 30 patients with melasma. The product was applied on one side of the face and the vehicle on the other, twice daily during 3 months. Standardized photographs were taken using RBX technology on the three visits (basal, at one and a half months and at 3 months). The main variable to determine the efficacy was the improvement of the hemifacial Melasma Area Severity Index (MASI). Other variables were determined such as improvement perceived by the investigator, improvement perceived by the patient, impact on quality of life or side effects. RESULTS: The MASI improvement at 3 months of treatment was significant on the treated side vs. the vehicle side, reaching an improvement of 70%, which is comparable to the percentage of improvement described with hydroquinone. No notable side effects were detected, in spite of a significant percentage of patients included in the study citing a history that could be compatible with sensitive skin. CONCLUSIONS: This new combination of retinoids and depigmenting agents proved to be effective and safe in the treatment of melasma.